Transparency notification

Brussels (Belgium), 15 December 2016 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 12 December 2016, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.).

BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had increased and has crossed the 3% threshold.

On 9 December 2016, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 840 557 UCB shares with voting rights (versus 5 820 942 UCB shares in its previous notification dated 6 December 2016), representing 3.00% of the total number of shares issued by the company (194 505 658) (versus 2.99% in the notification dated 6 December 2016).

2. Content of the notification

The transparency notification dated 12 December 2016 included the following information:

• Reason for the notification: Acquisition or disposal of voting securities or voting rights
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement:

• Date on which the threshold is crossed: 9 December 2016.
• Threshold crossed (in %): 3%.
• Denominator: 194 505 658.
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the PDF which is attached to the notification.

• Additional information:

The disclosure obligation arose due to voting rights for BlackRock, Inc. going above 3%.

3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following link.

For further information, UCB:

Investor Relations
Antje Witte         
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news